Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 9/20 | 0.49 |
| ▸ | PLCG2 | P16885 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | FPR2 | P25090 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3749289 | 0.99 | PLCG2 (0.49) | HRH3HRH4NPC1RAB9ALTA4H | |
| SCHEMBL3745388 | 0.83 | KMT2A (0.63) | LTA4HPLCG2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL13051012 | 0.83 | SMN1; SMN2 (0.55) | HRH3HRH4NPC1RAB9ALTA4H | |
| SCHEMBL744973 | 0.78 | LTA4H (0.65) | LTA4HKCNH2 | |
| SCHEMBL743937 | 0.77 | LTA4H (0.63) | LTA4HKCNH2 | |
| SCHEMBL12334808 | 0.74 | HRH4 (0.81) | HRH3HRH4NPC1RAB9AFPR2 | |
| SCHEMBL3745417 | 0.72 | XDH (0.52) | NPC1RAB9ALTA4HPLCG2KCNH2 | |
| SCHEMBL29944207 | 0.72 | HRH4 (0.76) | HRH3HRH4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2345954 | 0.72 | HRH4 (0.76) | HRH3HRH4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3746253 | 0.71 | CYP1A2 (0.51) | LTA4HKCNH2CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430019-B1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-18 | — | — | EP | disclosed |
| EP-2430019-B1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-18 | — | — | EP | disclosed |
| US-8399465-B2 | Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2013-03-19 | — | — | US | disclosed |
| US-8399465-B2 | Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2013-03-19 | — | — | US | disclosed |
| US-8399465-B2 | Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2013-03-19 | — | — | US | disclosed |
| EP-2430019-A1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | Janssen Pharmaceutica, N.V. (BE) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010132599-A1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132599-A1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292208-A1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292208-A1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292208-A1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292208-A1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTC4S, LTB4R | HRH3 111/4885HRH4 15/4885NPC1 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.